The heritability of fatal coronary artery disease may be as high as 50%.
Mendelian randomization in 1 million people: statin-like genetics cut dementia risk 76-82%
Summarises Dr Stanfield's video on a Mendelian randomization study of over a million people. Short RCTs show no cognitive harm or benefit and observational studies suggest protection; genetic variants mimicking lifelong statin and ezetimibe action were linked to 76-82% relative dementia risk reduction, implying long-term benefit missed by short trials. The video also notes treating hearing loss, vision loss and midlife depression.


